Sodium glucose transporter 2 inhibition maintains kidney antibacterial response by decreasing complement C1q
Authors:
Open Access
- 21 January 2026
- journal article
- Published by Elsevier in Kidney International
- Vol. 109 (5) , 894-906
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (EXC2151)
- Deutsche Forschungsgemeinschaft (390873048)
- Deutsche Forschungsgemeinschaft (466687329)
- Deutsche Forschungsgemeinschaft (450775971)
- Deutsche Forschungsgemeinschaft (264599542)
- Deutsche Forschungsgemeinschaft (FOR 5427/1)
- Deutsche Forschungsgemeinschaft (SFB1192)
This publication has 62 references indexed in Scilit:
- Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large TrialsAdvances in Therapy, 2024
- Updates on New Therapies for Patients with CKDKidney International Reports, 2023
- Immune defenses in the urinary tractTrends in Immunology, 2023
- Complement catalyzing glomerular diseasesCell and tissue research, 2021
- Single-Cell Profiling Reveals Sex, Lineage, and Regional Diversity in the Mouse KidneyDevelopmental Cell, 2019
- Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2Diabetologia, 2018
- Complement Activation in Patients With Diabetic NephropathyKidney International Reports, 2018
- Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification systemInternational Journal of Antimicrobial Agents, 2011
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Restoration of C1q levels by bone marrow transplantation attenuates autoimmune disease associated with C1q deficiency in miceEuropean Journal of Immunology, 2004